HeartFlow CMO Rogers Campbell Buys 12,329 Shares in Bold Bet on Undervalued 3‑D Cardiac Imaging Amid CFO Sell‑off Disparity

Insider Buying Spurs Optimism at HeartFlow

HeartFlow, Inc. (HEAR) saw a notable uptick in insider activity on September 18, 2026, when Chief Medical Officer Rogers Campbell executed a Rule 10b5‑1 trading‑plan purchase of 12,329 shares at $8.33 (≈ $98,788 total). A second purchase of 850 shares at $2.22 followed, bringing his post‑transaction holdings to 99,638 shares. This is the most substantial buying move by Campbell in the past year and the first under the new trading plan adopted on June 16, 2026. The timing—just days after a modest decline in the stock price—suggests a belief that the 3‑D cardiac imaging platform is still undervalued.

What It Means for Investors

Campbell’s recent buying stands in sharp contrast to the wave of selling by CFO Vikram Verghese in mid‑September. While Verghese’s sales (over 30,000 shares at $50–$51 each) raised questions about internal confidence, Campbell’s purchases hint at a divergent view among senior leadership. Investors should note that his holdings now represent roughly 10% of outstanding shares, a significant concentration that could signal a bullish outlook. If the company continues to meet revenue and earnings targets—its 52‑week high of $52.22 and a 40.31% annual gain—this insider buying could reinforce market confidence and support a rally.

Rogers Campbell: A Profile of Patience and Discipline

Examining Campbell’s transaction history reveals a pattern of disciplined, rule‑based trading. Since April 1, 2026, he has alternated between sizable purchases (e.g., 40,766 shares at $2.22) and modest sales (e.g., 9,219 shares at $41.23), often executing through the same 10b5‑1 plan. His option sales—totaling over 90,000 shares—are spread over months and tied to vesting schedules, indicating a long‑term commitment rather than a short‑term speculation. Unlike the CFO’s sporadic large sales, Campbell’s trades are evenly spaced and generally occur at lower prices, suggesting a strategy aimed at accumulating value while mitigating market impact.

Implications for HeartFlow’s Future

The dual narratives—CFO selling, CMO buying—highlight a complex insider sentiment landscape. For HeartFlow’s core business, the recent uptick in medical‑device sales and expanding payer coverage could justify a higher valuation, aligning with Campbell’s buying pattern. However, the CFO’s selling may reflect concerns about short‑term liquidity or a desire to diversify. The market will likely weigh both signals: Campbell’s buying could buoy the stock, while Verghese’s selling might temper enthusiasm. As HeartFlow advances its AI‑driven diagnostic platform, investors should monitor subsequent insider filings and quarterly earnings to gauge whether leadership’s actions translate into sustainable growth.